Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibuprofen Trelamine SCHEMBL30346084 | 1.00 | PTGS2 (0.57) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Ibuprofen Trelamine SCHEMBL30345799 | 1.00 | PTGS2 (0.57) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Ibuprofen Trelamine SCHEMBL2575591 | 0.99 | PTGS2 (0.56) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Ibuprofen Trelamine SCHEMBL25249124 | 0.99 | PTGS2 (0.56) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Ibuprofen Trelamine SCHEMBL16049968 | 0.96 | PTGS2 (0.54) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL3824048 | 0.90 | PTGS2 (0.56) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Hydrochloric Acid SCHEMBL16011709 | 0.90 | PTGS2 (0.53) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Hydrochloric Acid SCHEMBL16011748 | 0.89 | PTGS2 (0.52) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL30345985 | 0.88 | PTGS2 (0.54) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL17084613 | 0.88 | PTGS2 (0.56) | PTGS2PTGS1LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024273-A1 | TOPICAL ADMINISTRATION OF 2-(DIETHYLAMINO)ETHYL 2-(4-ISOBUTYLPHENYL)PROPRIONATE FOR TREATMENT OF DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2024-01-25 | — | — | US | claimed |
| EP-2849738-B1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO LTD (CN) | 2023-12-06 | — | — | EP | claimed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | claimed |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | claimed |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | claimed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | claimed |
| US-9718766-B2 | High penetration drugs and their compositions thereof for treatment of parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2017-08-01 | — | — | US | claimed |
| EP-2994453-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | Techfields Pharma Co., Ltd. (CN) | 2016-03-16 | — | — | EP | claimed |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2016-01-07 | — | — | US | claimed |
| WO-2014139161-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | TECHFIELDS PHARMA CO., LTD. (CN) | 2014-09-18 | — | — | WO | claimed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | claimed |
| EP-4222139-A4 | TOPICAL ADMINISTRATION OF 2- (DIETHYLAMINO) ETHYL 2- (4-ISOBUTYLPHENYL) PROPIONATE FOR TREATMENT OF DISEASES | TECHFIELDS INC. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240024273-A1 | TOPICAL ADMINISTRATION OF 2-(DIETHYLAMINO)ETHYL 2-(4-ISOBUTYLPHENYL)PROPRIONATE FOR TREATMENT OF DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2024-01-25 | — | — | US | disclosed |
| US-20230270710-A1 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVE | ZHEJIANG YUEJIA PHARMACEUTICALS CO LTD (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230270710-A1 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVE | ZHEJIANG YUEJIA PHARMACEUTICALS CO LTD (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-2370406-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | Yu, Chongxi (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-2041068-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION RATE | Techfields Biochem Co. Ltd (CN) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008010025-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION RATE | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | PTGS2 100/4885PTGS1 95/4885LMNA 1782/4885 |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | PTGS2 366/4885PTGS1 333/4885LMNA 3766/4885 |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | PTGS2 619/4885PTGS1 707/4885LMNA 1760/4885 |
| US-20230270710-A1 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVE | PTGES, PTGES2, PTGER1 | PTGS2 9/4885PTGS1 6/4885LMNA 3243/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | PTGS2 7/4885PTGS1 4/4885LMNA 2799/4885 |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | CPA3, HCAR2, HRH4 | PTGS2 62/4885PTGS1 81/4885LMNA 2722/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | PTGS2 7/4885PTGS1 4/4885LMNA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.